We have now finished recruiting for the first of two clinical trials investigating JAK inhibitors in the management of Alopecia Areata being conducted by Pfizer. Our first patients are approaching the half way point of the study.
In the UK there are 5 sites in Brighton, Southampton, Glasgow, Dundee and London.
The first study we are doing has a number of different arms comparing alternative dosing regimens with loading doses (high dose for initial 4 weeks) followed by different strengths, vs steady dosing, vs placebo. 
Even if selected for the placebo, there is an extension phase meaning after the first 24 weeks all patients will have access to active drug. Patients have to have 50% hair loss or more, with no evidence of spontaneous regrowth in the preceding 6 months to eligible.
The second study is a longer term study over 2 years with a lower threshold for entry (25% loss or more). Patients enrolled in the first study can continue in the second study if they want to which is obviously good news for the responders who might dread having to stop the medication.
The recruitment for the second study is on hold due to Covid 19 but as soon as hospitals start getting back to normal, we will start inviting patients for a screening visit.
This is a great step forward for patients suffering with alopecia who wish to pursue treatment but it is only a first step.